Skip to main content
. 2019 Sep 30;12(1):99–109. doi: 10.4168/aair.2020.12.1.99

Table 4. Clinical features of responders and non-responders after 1 year of AIT.

Characteristics Responder (n = 34) Non-responder (n = 14) P-value
Age (yr) 42.20 ± 12.51 46.00 ± 11.70 0.279
Females 17 (50.0) 8 (57.1) 0.756
BMI (kg/m2) 24.45 ± 3.13 22.93 ± 4.61 0.218
Age of asthma onset (yr) 31.36 ± 14.36 38.37 ± 10.05 0.046
Age of starting ICS (yr) 36.90 ± 12.73 40.84 ± 10.98 0.241
Age of starting AIT (yr) 40.09 ± 12.39 44.38 ± 11.77 0.198
Time from symptom onset to starting ICS (mon) 55.99 ± 81.58 31.13 ± 43.38 0.536
Time from starting ICS to starting AIT (mon) 18.01 ± 19.96 24.53 ± 32.80 0.427
Time from symptom onset to starting AIT (yr) 8.73 ± 8.03 6.00 ± 4.48 0.273
Allergic rhinitis 33 (97.1) 10 (71.4) 0.059
Smoking status -
Never-smoker 26 (79.5) 12 (85.7)
Ex-smoker 4 (11.8) 1 (7.1)
Current smoker 4 (11.8) 1 (7.1)
Prebronchodilator FEV1 (% predicted) 87.41 ± 12.88 79.12 ± 19.66 0.133
FEV1/FVC (%) 79.84 ± 7.09 80.32 ± 58.01 0.940
Allergen
House dust mites 24 (70.6) 11 (78.6) 0.728
Tree pollens 12 (35.3) 4 (28.6) 0.746
Weed pollens 8 (23.5) 5 (35.7) 0.480
Dog dander 6 (17.6) 1 (7.1) 0.656
Cat dander 2 (5.9) 1 (7.1) > 0.900
No. of allergens 2.05 ± 1.22 1.66 ± 0.66 0.759
AHR 19/25 (76.0) 7/9 (77.8) > 0.900

Values are presented as means ± standard deviations or number (%).

AIT, allergen immunotherapy; BMI, body mass index; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; AHR, airway hyperresponsiveness.